PharmaShots

JUNE 23, 2023

Gilead Receives EMA’s CHMP Positive Opinion of Trodelvy (sacituzumab govitecan) for Pre-Treated HR+/HER2- Metastatic Breast Cancer Date: June 23, 2023 | Tags: Gilead, Trodelvy, sacituzumab govitecan, HR+/HER2- Metastatic Breast Cancer, Regulatory, EMA, CHMP, Positive Opinion Sarepta Therapeutics’ Elevidys Receives the US FDA’s Accelerated (..)

FDA 40

FDA 40

PharmaShots

MARCH 9, 2023

Her notable achievements can be attributed to the fact that she has been acclaimed with the Kenneth Rainin Foundation Synergy Award, Robert Wood Johnson Harold Amos Medical Faculty Development Award, Immunology Faculty Mentor of the Year, and Gastroenterology & Hepatology Teaching Award. and Banco Bilbao Vizcaya Argentaria S.A

FDA 40

FDA Pharmaceutical Companies Pharmaceutical Companies Immunization 40

European Pharmaceutical Review

MAY 11, 2023

1 This is assuming a $1M price tag for all gene therapies. In 2015, she joined Astellas Pharma, Northbrook, IL, and served as Global Lead for Immunology, CNS and Neuromuscular Indications and eventually as Global Medical Lead for the Muscle TA. What are the emerging modalities in the gene therapy sector?

FDA 72

FDA 72

European Pharmaceutical Review

DECEMBER 27, 2023

For example, the use of granulocyte colony stimulating factor (G-CSF) in cases of early severe or prolonged haematological toxicities was not allowed initially because of immunological properties. This is in addition to its considerable price tag.

Adverse Reactions 86

Adverse Reactions Immunization Medical Schools Chemotherapy 86